Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3152 results found

2026 ∙ Landicho, J. Bravo, T. A. Wachinger, J. Silvestre, C. Barnighausen, K. Scott, K. Barnighausen, T. McMahon, S. A. Renosa, M. D. C.

Vaccine preferences and their role for vaccine confidence and uptake: a meta-ethnography

  • All age groups
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Tololiu, K. E. Kurnianto, A. A. Dulahu, W. Y. Kocsor, F. Csokasi, K.

A meta-analysis of digital interventions to reduce vaccination-related pain in children

  • Newborn
  • Children
  • Adolescents
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Dhayfule, D. Wu, Y. H. Ashyani, A. Li, M. C. Tsai, C. S. Chen, P. L. Nordling, T.

A meta-analysis of vaccine efficacy from phase III clinical trials of approved vaccines against SARS-CoV-2 and variants

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Ndzouboukou, J. L. B. Kamara, A. A. Ullah, N. Lei, Q. Fan, X. L.

A Meta-Analysis on the Immunogenicity of Homologous versus Heterologous Immunization Regimens against SARS-CoV-2 Beta, Delta, and Omicron BA.1 VoCs in Healthy Adults

  • Adults
  • Older adults
  • COVID-19
  • Administration
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Banga Ndzouboukou, J. L. Kamara, A. A. Ullah, N. Lei, Q. Fan, X. L.

A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Farina, S. Maio, A. Zaino, A. Russo, L. Ricciardi, W. Ieraci, R. Villani, L.

A review of childhood rotavirus vaccination policies and a presentation of vaccine coverage trends at national and regional level, Italy, 2016 to 2023

  • Europe
  • Italy
  • Newborn
  • Children
  • Rotavirus
  • Coverage
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Hamashima, Y. Breheny, K. Davies, S. R. Dawson, S. Thornton, Z. A. Aiton, E. Caldwell, D. M. Christensen, H. Higgins, J. P. T. Yates, J. Letley, L. French, C. E.

A synthesis of economic data from randomized trials of recipient-focused interventions to increase vaccine uptake

  • All age groups
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Vittrup, D. M. Charabi, S. Jensen, A. Stensballe, L. G.

A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age

  • Newborn
  • Measles
  • Safety
  • Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Kitano, T. Salmon, D. A. Dudley, M. Z. Saldanha, I. J. Thompson, D. A. Engineer, L.

A Systematic Review and Meta-Analysis of Health-State Utility Values for Infectious Diseases With Pandemic Potential and Associated Vaccine Adverse Reactions

  • All age groups
  • Safety
Methodological quality (AMSTAR 2):
High
2025 ∙ Green, R. Marjenberg, Z. Lip, G. Y. H. Banerjee, A. Wisnivesky, J. Delaney, B. C. Peluso, M. J. Wynberg, E. Abduljawad, S.

A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Low
Loading...